Skip to main content

Table 1 Clinical and pathological characteristics of the cohort

From: Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

 

Mean ± SD

N

Age (years)

63.5 ± 6.5

98

Prostatic volume (c.c)

44.4 ± 22.4

98

Testosterone (nmol/L)

13.9 ± 4.9

98

Total PSA (ng/mL)

9.7 ± 8.20

98

  

N (%)

BMI (kg/m2)

< 25

21 (21.7)

25–29.99

50 (51.6)

≥ 30

26 (26.7)

Total PSA (µg/L)

< 4

7 (7.2)

4–10

60 (61.9)

> 10

30 (30,9)

ISUP GG

 Low risk

Group I

38 (38,8)

Group II

24 (24,5)

 High risk

Group III

19 (19.3)

Group IV

10 (10.2)

Group V

7 (7.2)

T pathological stage

≤ T2a

69 (70.4)

T3, T4

29 (29,6)

No pathological stage

NX

53 (55.8)

N0

36 (37.9)

N1

6 (6.3)

  1. N number of patients, SD standard deviation, BMI body mass index, ISUP GG ISUP Grade Groups based on the Gleason score as follows: (Gleason score ≤ 6 group I; 3 + 4=7 group II; 4 + 3=7 group III; 4 + 4=8 group IV; and 9–10 group V); T-stage tumor category; N lymph node category
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us